MX2018013177A - Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas. - Google Patents

Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.

Info

Publication number
MX2018013177A
MX2018013177A MX2018013177A MX2018013177A MX2018013177A MX 2018013177 A MX2018013177 A MX 2018013177A MX 2018013177 A MX2018013177 A MX 2018013177A MX 2018013177 A MX2018013177 A MX 2018013177A MX 2018013177 A MX2018013177 A MX 2018013177A
Authority
MX
Mexico
Prior art keywords
fusion protein
ccl3 variant
cross
related applications
amino acid
Prior art date
Application number
MX2018013177A
Other languages
English (en)
Inventor
Hyun Choi Byung
Kyung Lee Jun
Gyun KIM Jong
Youn Nam Su
Gi Kim Seul
Young Park Ju
Rae Lee Na
Hong Kim Ki
Woong Oh Se
Yub Shin Seung
Woong Kang Ho
Jin Ahn Su
Yong Chung Soo
Hyung Lee June
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2018013177A publication Critical patent/MX2018013177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona una proteína de fusión que tiene una variante de CCL3 con persistencia in vivo, estabilidad de proteínas y actividad farmacológica mejoradas y un uso de la misma, más particularmente, una proteína de fusión que comprende una variante de CCL3 y una región Fc de inmunoglobulina y un uso de la misma como agente terapéutico para la linfopenia, cáncer o infección, en el que se elimina un aminoácido N-terminal de un CCL3a o CCL33 de tipo salvaje y un aminoácido en una posición específica se sustituye con un aminoácido diferente en la misma posición que el CCL3a de tipo salvaje o CCL33 en la variante CCL3.
MX2018013177A 2016-04-29 2017-04-19 Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas. MX2018013177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160053018A KR20170123849A (ko) 2016-04-29 2016-04-29 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
PCT/KR2017/004199 WO2017188653A1 (en) 2016-04-29 2017-04-19 Fusion protein comprising ccl3 variant and use thereof cross-reference to related applications

Publications (1)

Publication Number Publication Date
MX2018013177A true MX2018013177A (es) 2019-05-27

Family

ID=60160838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013177A MX2018013177A (es) 2016-04-29 2017-04-19 Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.

Country Status (13)

Country Link
US (1) US11046742B2 (es)
EP (1) EP3448880A4 (es)
JP (1) JP6820123B2 (es)
KR (1) KR20170123849A (es)
CN (1) CN109328194B (es)
AU (1) AU2017256464B2 (es)
BR (1) BR112018072045A8 (es)
CA (1) CA3021680C (es)
MX (1) MX2018013177A (es)
NZ (1) NZ748614A (es)
RU (1) RU2727715C2 (es)
WO (1) WO2017188653A1 (es)
ZA (1) ZA201807140B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021024419A1 (ja) * 2019-08-07 2021-02-11 平田機工株式会社 医薬組成物
CN117466986A (zh) * 2023-10-30 2024-01-30 中南大学 一种趋化因子ccl3的制备方法及其在制备肿瘤免疫治疗药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627003A1 (en) * 1991-12-23 1994-12-07 British Bio-Technology Limited Stem cell inhibiting proteins
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1578917A4 (en) * 2001-07-19 2008-01-23 Perlan Therapeutics Inc MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
IL162600A0 (en) * 2001-12-17 2005-11-20 Applied Research Systems Cc-chemokine mutants as cc-chemokine antagonists
WO2004062688A2 (en) * 2002-12-23 2004-07-29 Applied Research Systems Ars Holding N.V. Use of cc-chemokine mutants against liver diseases
EP1507147A1 (en) 2003-08-12 2005-02-16 Erasmus University Medical Center Rotterdam Method for detecting low levels of a fusion protein
CN1902223A (zh) * 2003-12-30 2007-01-24 惠氏公司 抑制副粘病毒感染的抗病毒组合物
US7638319B2 (en) * 2005-03-07 2009-12-29 New York University Method for determining co-receptor selectivity of Human Immunodeficiency Virus-1
AU2006280004A1 (en) * 2005-08-12 2007-02-22 Schering Corporation MCP1 fusions
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
US8445442B2 (en) 2007-04-26 2013-05-21 University Of Vermont And State Agricultural College CCL18 and CCL3 methods and compositions for detecting and treating cancer
JP5577243B2 (ja) * 2007-05-30 2014-08-20 ポステク アカデミー−インダストリー ファウンデイション 免疫グロブリン融合タンパク質
AU2011268934B2 (en) 2010-06-25 2015-09-10 Nykode Therapeutics ASA Homodimeric protein constructs
WO2012023631A1 (ja) * 2010-08-19 2012-02-23 株式会社Eci ヒートショックプロテイン（ｈｓｐ）とｅｃｉ３０１ポリペプチドを含む癌細胞の増殖を抑制するための医薬組成物ならびにそれを用いた癌の治療方法
EP2714065A4 (en) * 2011-06-01 2015-04-08 Jyant Technologies CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, PROCESS FOR THEIR MANUFACTURE AND USE
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US20160115216A1 (en) 2013-06-07 2016-04-28 Novo Nordisk A/S Method for Making Mature Insulin Polypeptides

Also Published As

Publication number Publication date
CN109328194A (zh) 2019-02-12
CA3021680A1 (en) 2017-11-02
RU2727715C2 (ru) 2020-07-23
BR112018072045A2 (pt) 2019-06-04
AU2017256464A1 (en) 2018-12-13
JP2019516363A (ja) 2019-06-20
BR112018072045A8 (pt) 2023-01-17
RU2018141714A3 (es) 2020-05-27
ZA201807140B (en) 2019-07-31
JP6820123B2 (ja) 2021-01-27
CN109328194B (zh) 2022-04-19
WO2017188653A1 (en) 2017-11-02
US20190153055A1 (en) 2019-05-23
NZ748614A (en) 2020-04-24
US11046742B2 (en) 2021-06-29
EP3448880A1 (en) 2019-03-06
AU2017256464B2 (en) 2019-08-15
EP3448880A4 (en) 2019-12-04
KR20170123849A (ko) 2017-11-09
RU2018141714A (ru) 2020-05-27
CA3021680C (en) 2022-03-15

Similar Documents

Publication Publication Date Title
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
PH12020551026A1 (en) Fusion protein comprising il-2 protein and cd80 protein, and use thereof
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2020010912A (es) Proteínas il-15/il-15ra de fusión a fc heterodiméricas y usos de las mismas.
TW201613958A (en) MIC-1 fusion proteins and uses thereof
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2017006866A (es) Pares de unión para producción de péptidos.
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
EA202091342A3 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
EA201690469A1 (ru) Слитый белок
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
EA201591421A1 (ru) Препараты полипептида фактора ix
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.
MX2019006446A (es) Métodos para inducir tolerancia inmunológica a factores de coagulación.
WO2014169274A3 (en) Modified proteins and methods of use thereof
AR102120A1 (es) Interferón modificado con inmunogenicidad reducida
EA201991340A1 (ru) Способы индуцирования иммунологической толерантности к факторам свертывания крови